The process of drug development, review, delivery, and use is one that involves many stakeholders, including industries, regulators, physicians, and patients. All play roles that influence treatment outcomes. The illness experiences and perceptions of patients are key components to understanding a disease and providing safe and effective treatments. Looking at the experience of the IBS community with the drug alosetron as an example, this article reflects upon how treatment delivery can break down, and actions that can help ensure that safer, effective, treatments are made available to patients in need.
Fact Sheet: IBS in the Real World SurveyRWS
Sponsored by IFFGD, this quantitative research study was conducted in 2002 among 350 U.S. adults who reported a diagnosis of Irritable Bowel Syndrome. A glimpse into the real world of living with the disease, symptoms, treatment, side effects, and the overall impact that IBS has on lives.
Sponsored by IFFGD, in collaboration with the UNC Center for Functional GI and Motility Disorders, the findings in this comprehensive 2007 online survey show that much more needs to be done to develop and deliver satisfactory treatment to IBS sufferers.
Documents listed on this page are available for download in Adobe’s PDF format. If you don’t have Adobe Reader, please visit Adobe’s site to download it. It’s free!